Amanda Adler
Director, Diabetes Trials Unit
Amanda Adler, MD, PhD, FRCP is Professor of Diabetic Medicine and Health Policy at Oxford University, and director of the Diabetes Trials Unit within the Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM). She trained in economics, medicine, and epidemiology in the US, and pharmacoepidemiology and pharmacovigilance in the UK.
She chairs a Technology Appraisal Committee at the National Institute for Health and Care Excellence (NICE) evaluating drugs and devices across disease areas which she has done since 2009. Also with NICE, she chaired the Clinical Guidelines for Newer Agents for Type 2 Diabetes and the Quality Standard for Diabetes, advises the Connect Project, and chaired decisions for the Cancer Drug Fund. In 2019, Professor Adler received an award for Distinguished Contribution to NICE at the Parliamentary ceremony celebrating NICE’s 20th anniversary.
She is a practicing physician at Addenbrooke's Hospital and Royal Papworth Hospital in Cambridge. She advises the UK National Screening Committee and the World Health Organisation as a technical expert. She serves on an Expert Advisory Group for the UK Commission on Human Medicines, and chaired the Expert Group on the Safety of Insulin for the UK’s Medicines and Health Products Regulatory Agency. She is a Fellow of the Royal Statistical Society.
Professor Adler supports projects that set priorities under universal health coverage working in collaboration with the UK government, NICE Scientific Advice, NICE International, the International Decision Support Initiative (iDSI), the World Bank, and the Organisation for Economic Co-operation and Development.